Testing a blood-monitor device during lung cancer immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent (and understand what the study involves).
- You are 18 years or older.
- You have non-small cell lung cancer that cannot be cured (stage III or IV) and is being treated for palliation.
- Your cancer treatment includes immunotherapy (using immunotherapy alone, in combination with another immunotherapy, or with chemotherapy).
- You are not currently taking part in another interventional clinical study.
- Your hemoglobin (Hb) is not below 9 g/dl.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.